<DOC>
	<DOCNO>NCT02491268</DOCNO>
	<brief_summary>Epidemiological , clinicopathological animal study show vascular disease various form contributes cognitive decline . Increasing age strong risk dementia irrespective whether result vascular etiology neurodegenerative disease process Alzheimer 's disease ( AD ) . AD vascular cognitive impairment , two common cause dementia , represent two extreme spectrum disorder ; however , number entity , posse vary degree neurodegenerative vascular pathology , occur . The pure form disorder prefer convenience label , treat manage condition within spectrum norm rather exception dementia advance . Therefore , combinatorial therapy direct vascular neurodegenerative aspect dementia promise approach treatment dementia elderly . Cilostazol act antiplatelet agent pleiotropic effect base phosphodiesterase-3-dependent mechanism . Increasing evidence suggest cilostazol offer endothelial protection , via pleiotropic effect . Intriguingly , cilostazol show decrease amyloid beta ( Abeta ) accumulation protect Abeta-induced cognitive deficit experimental model . In pilot study 10 patient moderate AD ( mean MMSE score , 11.9 point ) receive donepezil , cilostazol add-on treatment 5-6 month demonstrate significantly increase MMSE score comparison baseline . Moreover , cilostazol show effective prevent cognitive decline patient AD cerebrovascular disease , mild cognitive impairment ( MCI ) , mild dementia receive donepezil . These result highlight need comprehensive prospective cohort study analyze effect cilostazol preservation cognitive function patient early-stage cognitive impairment , namely MCI .</brief_summary>
	<brief_title>A Trial Cilostazol Patients With Mild Cognitive Impairment ( COMCID )</brief_title>
	<detailed_description />
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Mild Cognitive Impairment</mesh_term>
	<mesh_term>Cilostazol</mesh_term>
	<criteria>1 . Age 5584 ( inclusive ) 2 . Study partner life subject available visit 3 . Patients MCI satisfy core clinical criterion National Institute AgingAlzheimer Association MCI ( nearly equivalent mild neurocognitive disorder Diagnostic Statistical Manual Mental Disorders , Fifth Edition ) also satisfy follow three criterion : ) Memory complaint subject study partner Type I : Memory complaint subject verify study partner Type II : Otherwise , memory complaint study partner evidence memory impairment Note ) Memory complaint subject verify study partner exclude . ii ) MiniMental State Examination ( MMSE ) score 22 28 ( inclusive ) iii ) Clinical Dementia Rating ( CDR ) = 0.5 4 . Written inform consent provide study participation 1 . Parkinson 's disease , Huntington 's disease , normal pressure hydrocephalus , progressive supranuclear palsy , epilepsy , multiple sclerosis , cerebral infection , subsequent complication cause head trauma . 2 . Findings multiple infarction , brain tumor , subdural hematoma MRI perform within 48 week provisional registration . 3 . Contraindications MRI magnetic body metal . 4 . History major depression bipolar disorder within 48 week provisional registration , alcohol substance abuse within 96 week provisional registration , diseases unstable condition . 5 . Poorly control diabetes mellitus ( HbA1c &gt; 9.0 % ) within 24 week provisional registration . 6 . Cognitive impairment due deficiency vitamin B12 folate . 7 . Neurosyphilis . 8 . Thyroid function abnormality . 9 . Psychoactive drug within 4 week provisional registration . 10 . Oral anticoagulant within 4 week provisional registration . 11 . Double antiplatelet therapy ( cf . Aspirin , Clopidogrel Cilostazol ) within 4 week provisional registration . 12 . Poorly control diabetes mellitus treated insulin within 4 week provisional registration . 13 . Episode hypoglycemic attack loss consciousness within 4 week provisional registration . 14 . Antidementia drug within 4 week provisional registration . 15 . Participation new drug study Alzheimer 's disease . 16 . Current bleed bleeding disorder . 17 . Congestive heart failure . 18 . Coronary artery stenosis . 19 . Sustained high blood pressure within 2 week provisional registration . 20 . History drug hypersensitivity Cilostazol . 21 . The subject subject 's spouse pregnant breastfeeding time provisional registration . 22 . Difficulty neuropsychological test due hear visual impairment . 23 . Considered principal investigator ineligible .</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>84 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>